Yuko Matsunaga
-
- Antibiotic Use and Resistance 5
- Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria 9
- Pharmacology top 1%
- Antibiotics Pharmacokinetics and Efficacy 11
- Endocrinology top 5%
-
- Asthma and respiratory diseases 11
-
- Immune Cell Function and Interaction 8
- Immune Response and Inflammation 4
- interferon and immune responses 3
-
- Pneumonia and Respiratory Infections 4
- Co-authors
- Roger EcholsTsutae Den NagataMari AriyasuRichard G. WunderinkYohei DoiSimon PortsmouthMatteo BassettiKiichiro Toyoizumi
- Partner nations
- JapanUnited StatesGreece
In The Last Decade
Yuko Matsunaga
51 papers receiving 1.9k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Applied Microbiology and Biotechnology 394
- Molecular Medicine 853
- Pharmacology 651
- Endocrinology 131
- Critical Care and Intensive Care Medicine 101
Countries citing papers authored by Yuko Matsunaga
This map shows the geographic impact of Yuko Matsunaga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuko Matsunaga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuko Matsunaga more than expected).
Fields of papers citing papers by Yuko Matsunaga
This network shows the impact of papers produced by Yuko Matsunaga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuko Matsunaga. The network helps show where Yuko Matsunaga may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yuko Matsunaga, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 53 | |
| 2 | 2022 | 5 | |
| 3 | 2022 | 29 | |
| 4 | 2020 | 8 | |
| 5 | 2020 | 2 | |
| 6 | Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trialbreakdown → | 2020 | 319 |
| 7 | 2019 | 27 | |
| 8 | 2014 | 5 | |
| 9 | 2014 | 28 | |
| 10 | 2014 | 12 | |
| 11 | 2011 | 8 | |
| 12 | 2011 | 16 | |
| 13 | 2011 | 166 | |
| 14 | 2010 | 11 | |
| 15 | 2010 | 31 | |
| 16 | 2003 | 39 | |
| 17 | 2003 | 102 | |
| 18 | 2003 | 21 | |
| 19 | 2000 | 6 | |
| 20 | 1995 | 31 |
About Yuko Matsunaga
Yuko Matsunaga is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine and Pharmacology, having authored 51 papers that have together received 1.9k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (11 papers), Asthma and respiratory diseases (11 papers), Antibiotic Resistance in Bacteria (9 papers), Immune Cell Function and Interaction (8 papers), Antibiotic Use and Resistance (5 papers), Pneumonia and Respiratory Infections (4 papers), Immune Response and Inflammation (4 papers) and interferon and immune responses (3 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (394 citations), Molecular Medicine (853 citations) and Pharmacology (651 citations). Yuko Matsunaga has collaborated with scholars based in Japan, United States and Greece. Frequent co-authors include Roger Echols, Tsutae Den Nagata, Mari Ariyasu, Richard G. Wunderink, Yohei Doi, Simon Portsmouth, Matteo Bassetti, Kiichiro Toyoizumi, Hiromasa Inoue and Thomas P. Lodise. Their work appears in journals such as Nature Immunology, The Journal of Immunology and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.